Sunshine Biopharma Inc.

Sunshine Biopharma is a pharmaceutical company operating in the pharmaceutical testing services sector, as well as, in the research, development and commercialization of drugs for the treatment of cancer and other acute and chronic indications.

Certified Sample Testing Services

Sunshine Biopharma offers certified testing services of pharmaceutical and other industrial samples through its wholly owned subsidiary, Atlas Pharma Inc. To learn more, please visit Atlas Pharma's website ( or call 450-682-8000.

Generic Drugs - Coming Soon...

Sunshine Biopharma operates a wholly owned Canadian subsidiary (Sunshine Biopharma Canada Inc.) dedicated to bringing affordable essential medicines to patients in Canada and elsewhere around the world. The following are Sunshine Biopharma's initial medicines which will be available soon:

  • SBI-Anastrozole for treatment of Breast Cancer
  • SBI-Letrozole for treatment of Breast Cancer
  • SBI-Bicalutamide for treatment of Prostate Cancer
  • SBI-Finasteride for treatment of BPH (Benign Prostatic Hyperplasia)

Sunshine Biopharma is planning to bring to market 23 additional "essential medicines" over the next 12 to 18 months. Learn More...

Proprietary Drugs - In Development

Sunshine Biopharma's flagship anticancer compound, Adva-27a, is a small molecule that has recently been shown to be effective at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells and Uterine Sarcoma cells. These and other preclinical results have been published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012. Adva-27a is the only compound known that is capable of destroying Multidrug Resistant Cancer cells. We are planning to conduct our Adva-27a Phase I Clinical Trials on Pancreatic Cancer patients at McGill University's Jewish General Hospital in Montreal (Canada). Sunshine Biopharma is direct owner of all worldwide patents covering Adva-27a, including all issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029. More information is available under Drugs in Development.